Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
NCT ID: NCT05234229
Last Updated: 2024-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
254 participants
OBSERVATIONAL
2022-03-01
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In order to protect infants under 6 months of age, France has recommended since 2004 the cocooning strategy, which consists of vaccinating people likely to be in close contact with the infant during this period. This vaccination is therefore proposed to adults who are planning to have children, to the entourage of pregnant women, and in the immediate post-partum period for the mother (and people who were not vaccinated during pregnancy). This strategy was put in place following the international recommendation of a forum of scientific experts, the Global Pertussis Initiative.
In France, vaccination against pertussis is not currently recommended during pregnancy. There is no contraindication to vaccination during pregnancy and it is recommended in many countries.
Influenza is a viral respiratory infection caused by Myxovirus influenzae, which is highly contagious.
In France, vaccination against influenza is recommended for pregnant women, regardless of the trimester of pregnancy. It is also recommended for the entourage of infants under 6 months of age with risk factors for severe influenza.
There are few recent data in the scientific literature regarding influenza and pertussis vaccination coverage among pregnant or postpartum women in France. In addition, the COVID19 pandemic has recently reopened the debate on vaccination of the general population and caregivers. Knowing the current status of vaccination coverage among pregnant women and caregivers, their knowledge and fears regarding vaccination could help improve the information provided by healthcare staff.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants
NCT02511327
Increasing Influenza and Tdap Vaccination of Pregnant Women
NCT04444518
Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France
NCT06881953
Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy
NCT03096574
Group B Streptococcus: Attitudes to Immunisation in Pregnancy
NCT01982084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
covagrip women in immediate post partum
women in immediate post partum
Survey
Collection of immunization status by questionnaire
Caregivers
health care personnel
Survey
Collection of immunization status by questionnaire
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Survey
Collection of immunization status by questionnaire
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization in the post-partum service and within the last 5 days of delivery.
* women. caregivers
Exclusion Criteria
* Woman under legal protection,
* Delivery of a stillborn child,
* Premature delivery \< 35GA,
* Hospitalized newborn,
* Women who doesn't speak french.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean-Michel HASCOET
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean Michel HASCOET
Role: STUDY_DIRECTOR
Maternité Régionale Universitaire CHRU NANCY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternite Regionale Universitaire CHRU NANCY
Nancy, Lorraine, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021PI087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.